Dr. Nader H. Moniri

Associate Dean for Research and Professor of Pharmaceutical Sciences

 

A headshot of Dr. Moniri (College of Pharmacy) outdoors, with green shrubs and a lawn in the background.Education

Research Background and Interests

Dr. Moniri’s training has focused on molecular pharmacology and signal transduction of G protein-coupled receptors (GPCR)  as well as the design and development of novel agents which modulate GPCR function. Current research interests include characterization of free-fatty acid (FFA) GPCRs, and their role in human health and disease.

Our current projects focus on the role of FFA receptors, including the long-chain FFA receptors FFA1/GPR40 and FFA4/GPR120, as well as the short-chain FFA receptors FFA2/GPR43 and FFA3/GPR41 in metabolism, neurodegeneration, inflammation, and cancers. An NIH/NHLBI-funded grant also supports projects that seeks to understand the role of reactive oxygen species (ROS) in regulating the β2-adrenergic receptor (β2AR), which is critical in the treatment of airway disorders such as asthma and COPD.

Another recent NIH grant in collaboration with Dr. Clint Canal supports the study of the mechanisms of the drug of abuse xylazine on α2-adrenergic receptors. Along with Dr. Canal, Dr. Moniri is also co-founder of Channel Therapeutics, a biopharmaceutical company that seeks to develop drugs that act with high selectivity at muscarinic acetylcholine receptors for treatment of a variety of brain, gastrointestinal, urinary, and airway disorders. Dr. Moniri’s lab also collaborates with Dr. Raquib Hasan on three American Heart Association and one NIH-funded projects that examine the roles of various intracellular signaling pathways in hypertension.

Courses

  • PHA 329 Pharmacy Fundamentals
  • PHA 467 Endocrine Pharmacotherapy
  • PHA 468 Infectious Diseases Pharmacotherapy
  • PHA 547 Nervous System Pharmacotherapy
  • PHA 548/549 Project Development/Introduction to Research
  • PHA 537 Gastrointestinal & Musculoskeletal Pharmacotherapy
  • PHA 799 Thesis Research
  • PHA 899 Doctoral Research
Selected Publications
  • Karmokar PF, Murphy AJ, Moniri NH. The roles of free-fatty acid receptors in the pathophysiology of renal disorders. Journal of Pharmacology and Experimental Therapeutics. 393:104889, 1-16, 2026. PMID: 42096898
  • Mukti M and Moniri NH. Fueling the fire or dousing the flame? The unclear role of the free-fatty acid receptor-4 (FFA4/GPR120) in colorectal cancer. Biochemical Pharmacology. 250:117952, 1-9, 2026. PMID: 41956426
  • Karmokar PF and Moniri NH. The role of free-fatty acid receptors FFA1 and FFA4 in organ fibrosis. British Journal of Pharmacology. 183(7):1341-1363. PMID: 41555774
  • Moghaddam F, Binwal M*, Green AJ, Rambacher KM, Wood BJ, Murnane KS, Moniri NH. Agonism of FFA4/GPR120 activates tyrosine hydroxylase and confers neuroprotection from 6-OHDA-induced cytotoxicity in PC12 cells and in a rat 6-OHDA model of Parkinson’s Disease. Biochemical Pharmacology. 245:117685, 1-11, 2026. PMID: 41506541
  • Chen Y, Seto J, Obeng S, Mottinelli M, Mukhopadhyay S, Tyagi R, Hampson AJ, McCurdy CR, McMahon LR, Moniri NH, Canal CE. In vitro pharmacology of mitragynine at α-adrenoceptors. ACS Chemical Neuroscience 16(23):4531-4545, 2025. PMID: 41269061
  • Teyani RL and Moniri NH. Biased agonism at free-fatty acid receptor-4 (FFA4/GPR120). Pharmacology & Therapeutics. 266:108784, 1-9, 2025. PMID: 39719174
  • Higgins J, Carlisle JW, Moniri NH, Gupta S, Oduah E, Leal TA. Sotorasib for the treatment of locally advanced/metastatic non-small cell lung cancer. Future Oncology. 14796694:1-9, 2024. PMID: 39601038
  • Teyani RL, Moghaddam F, Moniri NH. ROS-mediated regulation of β2AR function: Does oxidation play a meaningful role towards β2-agonist tachyphylaxis in airway obstructive diseases? Biochemical Pharmacology. 226:116403, 1-7, 2024. PMID: 38945277
  • Singh K, Teyani RL, Moniri NH. Agonists and hydrogen peroxide mediate hyperoxidation of β2-adrenergic receptor in airway epithelial cells: Implications for tachyphylaxis to β2-agonists in constrictive airway disorders. Biomedicine and Pharmacotherapy, 168:115763, 1-13, 2023. PMID: 37865997
  • Teyani R and Moniri NH. Gut feelings in the islets: The role of the gut microbiome and the FFA2 and FFA3 receptors for short chain fatty acids on β-cell function and metabolic regulation. British Journal of Pharmacology, Commissioned Review, 1-7, 2023. PMID: 37620991
  • Swanson SM, Birnbaum A, Brackett C, Lipscomb J, Moniri NH, Swaan PW, Lei W, Farrell D. The Report of the 2022-2023 AACP Research and Graduate Affairs Committee. American Journal of Pharmaceutical Education. 87(8):100556, 1-4, 2023. PMID 37442437
  • Menon SN, Daniel ML, Zerin F, Ezewudo E, Simon NP, Green AJ, Pandey A, Mackay CE, Hafez S, Moniri NH, Hasan R. Neflamapimod inhibits endothelial cell activation, adhesion molecule expression and leukocyte attachment by inhibiting p38 MAPKα and NF-κB signaling. Biochemical Pharmacology. 214:115683, 1-14, 2023. PMID: 37429422
  • Karmokar PF and Moniri NH. Free-fatty acid receptor-1 (FFA1/GPR40) promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR, ERK1/2, STAT3 and EMT. Cancer Cell International, 23:126, 1-19, 2023. PMID: 37355607
  • Thurston MM, Moniri NH, Bowen JP, Winkles CL, Miller SW. Managing the “Three Cs” of Academic Literature Authorship: Contributions, Credit, and Conflict. American Journal of Pharmaceutical Education. 87: 100009, 1-4, 2023. PMID: 37288678
  • Karmokar PF and Moniri NH. Free-Fatty Acid Receptor-4 (FFA4/GPR120) differentially regulates migration, invasion, proliferation and tumor growth of papillary renal cell carcinoma cells. Biochemical Pharmacology. 213:115590, 1-13, 2023. PMID: 37201877
  • Rizzo AR and Moniri NH. Omadacycline for management of Mycobacterium abscessus infections: A review of its effectiveness, place in therapy, and considerations for use. BMC Infectious Diseases. 22(1):874, 1-11, 2022. PMID: 36419143
  • Karmokar PF and Moniri NH. Oncogenic signaling of the Free-Fatty Acid Receptors FFA1 and FFA4 in human breast carcinoma cells. Biochemical Pharmacology. 206:115308, 1-10, 2022. PMID: 36309079
  • Singh K, Senatorov IS, Cheshmehkani A, Karmokar PF, Moniri NH.  The skeletal muscle relaxer cyclobenzaprine is a potent non-competitive antagonist of histamine H1 receptors. Journal of Pharmacology and Experimental Therapeutics. 380(3):202-209, 2022.  PMID:  34992159
  • Moniri NH and Farah Q. Short-chain free-fatty acid G protein-coupled receptors in colon cancer. Biochemical Pharmacology.186:114483, 2021
  • Rambacher KM and Moniri NH. Cysteine redox state regulates human β2-adrenergic receptor binding and function. Scientific Reports, 10:2934, 1-15, 2020.
  • Senatorov IS, Cheshmehkani A, Burns RN, Singh, K, Moniri NH.  Carboxy-terminal phosphoregulation of the long splice isoform of Free-Fatty Acid Receptor-4 mediates β-arrestin recruitment and signaling to ERK1/2.  Mol. Pharmacol.  97:304-313, 2020.
News and Notes

Contact Dr. Nader H. Moniri


Moye Pharmacy and Health Sciences Center, #239
(678) 547-6246
moniri_nh@mercer.edu